When.com Web Search

  1. Ads

    related to: igf1r thyroid eye disease

Search results

  1. Results From The WOW.Com Content Network
  2. Insulin-like growth factor 1 receptor - Wikipedia

    en.wikipedia.org/wiki/Insulin-like_growth_factor...

    There is a 60% homology between IGF-1R and the insulin receptor. The structures of the autophosphorylation complexes of tyrosine residues 1165 and 1166 have been identified within crystals of the IGF1R kinase domain. [6] In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains.

  3. Graves' ophthalmopathy - Wikipedia

    en.wikipedia.org/wiki/Graves'_ophthalmopathy

    In mild disease, patients present with eyelid retraction. In fact, upper eyelid retraction is the most common ocular sign of Graves' orbitopathy. This finding is associated with lid lag on infraduction (Von Graefe's sign), eye globe lag on supraduction (Kocher's sign), a widened palpebral fissure during fixation (Dalrymple's sign) and an incapacity of closing the eyelids completely ...

  4. Insulin-like growth factor 1 - Wikipedia

    en.wikipedia.org/wiki/Insulin-like_growth_factor_1

    IGF-1 binds to at least two cell surface receptor tyrosine kinases: the IGF-1 receptor (IGF1R), and the insulin receptor. Its primary action is mediated by binding to its specific receptor, IGF1R, which is present on the surface of many cell types in many tissues [further explanation needed]. Binding to the IGF1R initiates intracellular signaling.

  5. Viridian's drug cuts thyroid eye disease symptoms in late ...

    www.aol.com/news/viridian-says-thyroid-eye...

    Veligrotug helped 64% of patients, when adjusted for placebo rates, achieve at least a 2-millimeter reduction in eye bulging after 15 weeks of treatment, Viridian said.

  6. Viridian Therapeutics To Test Next-Gen IGF-1R Antibody In ...

    www.aol.com/news/viridian-therapeutics-test-next...

    The FDA has signed off Viridian Therapeutics Inc's (NASDAQ: VRDN) investigational new drug (IND) application of VRDN-002. The Company's next-generation IGF-1R antibody, VRDN-002, is a humanized ...

  7. Graves' disease - Wikipedia

    en.wikipedia.org/wiki/Graves'_disease

    Thyroid-associated ophthalmopathy (TAO), or thyroid eye disease (TED), is the most common extrathyroidal manifestation of Graves' disease. It is a form of idiopathic lymphocytic orbital inflammation , and although its pathogenesis is not completely understood, autoimmune activation of orbital fibroblasts , which in TAO express the TSH receptor ...